Alzheon Appoints Franz Hefti, PhD, To Board Of Directors

Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that it has appointed Franz F. Hefti, PhD, to the company’s Board of Directors. Dr. Hefti’s leadership and expertise in drug development for Alzheimer’s disease will support Alzheon’s continued growth and advancement as a leading clinical-stage Alzheimer’s company.

Help employers find you! Check out all the jobs and post your resume.